| 000 | 01379 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250513143139.0 | ||
| 264 | 0 | _c19980716 | |
| 008 | 199807s 0 0 eng d | ||
| 022 | _a0195-668X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan Hout, B A | |
| 245 | 0 | 0 |
_aCosts and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. _h[electronic resource] |
| 260 |
_bEuropean heart journal _cApr 1998 |
||
| 300 |
_aD59-66 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAbciximab |
| 650 | 0 | 4 |
_aAngioplasty, Balloon, Coronary _xeconomics |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xeconomics |
| 650 | 0 | 4 |
_aCoronary Disease _xdrug therapy |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xeconomics |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xeconomics |
| 650 | 0 | 4 |
_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aBowman, L | |
| 700 | 1 | _aZelinger, D J | |
| 700 | 1 | _aSimoons, M L | |
| 773 | 0 |
_tEuropean heart journal _gvol. 19 Suppl D _gp. D59-66 |
|
| 999 |
_c9564259 _d9564259 |
||